Consider an SGLT-2 inhibitor for those with heart failure or chronic kidney disease or a GLP-1 agonist for secondary stroke and cardiovascular prevention in stroke patients with diabetes in addition to metformin if no contraindications [35]. This evidence concerns the gene SLC5A2 and Stroke.